 |
|
 |
Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching Phase 2 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes. 
|
Press Releases
June 10, 2013 Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel: Oramed to Present on Tuesday, June 11, 2013, at 3:10 p.m. (IDT) ... read more »
June 3, 2013 Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013 ... read more »
May 30, 2013 Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
May 28, 2013
Oramed CEO to Present at New York Biotechnology Association and The Israel Conference's Fast and CoolTM Session
May 17, 2013 Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. |
| Press Center | Terms & Conditions | Privacy Statement | Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed |